학술논문
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States
Document Type
article
Author
Lewis, Nathaniel M; Self, Wesley H; Gaglani, Manjusha; Ginde, Adit A; Douin, David J; Talbot, H Keipp; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; Ghamande, Shekhar A; McNeal, Tresa A; Shapiro, Nathan I; Gibbs, Kevin W; Files, D Clark; Hager, David N; Shehu, Arber; Prekker, Matthew E; Erickson, Heidi L; Gong, Michelle N; Mohamed, Amira; Johnson, Nicholas J; Srinivasan, Vasisht; Steingrub, Jay S; Peltan, Ithan D; Brown, amuel M; Martin, Emily T; Monto, Arnold S; Khan, Akram; Busse, Laurence W; Lohuis, Caitlin C ten; Duggal, bhijit; Wilson, Jennifer G; Gordon, Alexandra June; Qadir, Nida; Chang, Steven Y; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M; Kwon, Jennie H; Exline, Matthew C; Lauring, Adam S; Halasa, Natasha; Chappell, James D; Grijalva, Carlos G; Rice, Todd W; Rhoads, Jillian P; Jones, Ian D; Stubblefield, William B; Baughman, Adrienne; Womack, Kelsey N; Lindsell, Christopher J; Hart, Kimberly W; Zhu, Yuwei; Adams, Katherine; Patel, Manish M; Tenforde, Mark W; Collaborators, IVY Network
Source
Clinical Infectious Diseases. 75(Suppl 2)
Subject
Language
Abstract
Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use. Methods . In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression. Results . After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% confidence interval [CI]: 63-75%) overall, including 55% (29-72%) among immunocompromised patients, and 72% (64-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59-82%]), 91-180 days (71% [60-80%]), and 181-274 days (70% [54-81%]) postvaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18-65%) among immunocompetent patients. Conclusions . The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.